A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06055374 |
Recruitment Status :
Not yet recruiting
First Posted : September 26, 2023
Last Update Posted : September 26, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Atopic Dermatitis | Drug: BxC-I17e Drug: Placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 18 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of BxC-I17e Administered Subcutaneously in Patients With Moderate to Severe Atopic Dermatitis |
Estimated Study Start Date : | May 1, 2024 |
Estimated Primary Completion Date : | April 30, 2025 |
Estimated Study Completion Date : | August 30, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: BxC-I17e
|
Drug: BxC-I17e
Pharmaceutical form : solution for injection |
Placebo Comparator: Placebo
|
Drug: Placebo
Pharmaceutical form : solution for injection |
- Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: Baseline to Week 26 ]Incidence of treatment-emergent adverse events as assessed by CTCAE v5.0
- Incidence, severity and relationship of adverse events(AEs) [ Time Frame: Baseline to Week 26 ]Incidence, severity and relationship of adverse events as assessed by CTCAE v5.0
- Number of abnormalities and change from baseline in Vital signs [ Time Frame: Baseline to Week 26 ]Supine blood pressure and pulse rate, tympanic temperature, and respiratory rate
- Number of abnormalities in 12-lead electrocardiogram (ECG) [ Time Frame: Baseline to Week 26 ]PR interval, QRS interval, RR interval, QT interval and QT interval using Friderica's correction (QTcF)
- Number of abnormalities in clinical laboratory parameter [ Time Frame: Baseline to Week 26 ]Hematology, clinical chemistry, and urinalysis parameters
- Frequency and proportion of clinically significant finding of physical examination [ Time Frame: Baseline to Week 26 ]Assessments of the following body categories : skin, HEENT (head, eye, ears, nose, and throat), cardiovascular, respiratory, gastrointestinal, endocrine/metabolic, genitourinary, psychiatric, hematologic/lymphatics, musculoskeletal, neurologic, hepatic, and allergic/immunologic
- Proportion of patients who achieved the Investigator's Global Assessment (IGA) score of 0 or 1 [ Time Frame: Baseline to Week 14 ]The IGA is an assessment instrument used in clinical studies to rate the severity of Atopic dermatitis globally, based on a 5-point scale ranging from 0 (clear) to 4 (severe).
- Change and percent change in Body Surface Area (BSA) [ Time Frame: Baseline to Week 14 ]The BSA affected by atopic dermatitis will be assessed for each major section of the body (head, trunk, arms, and legs). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).
- Change and percent change in Eczema Area and Severity Index (EASI) [ Time Frame: Baseline to Week 14 ]The EASI is a composite index with scores ranging from 0 to 72. Higher scores indicates worse condition.
- Change and percent change in Scoring Atopic Dermatitis (SCORAD) [ Time Frame: Baseline to Week 14 ]The SCORAD is a clinical tool for assessing the severity of Atopic dermatitis. Total score ranged from 0 (absent disease) to 103 (severe disease).
- Change and percent change in Pruritus Numerical Rating Scale (NRS) [ Time Frame: Baseline to Week 14 ]The Pruritus NRS is a simple assessment tool used to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the' worst itch imaginable.
- Change and percent change in Dermatology Life Quality Index (DLQI) [ Time Frame: Baseline to Week 14 ]The DLQI is a validated questionnaire designed to measure the impact of skin disease on the Quality of Life. The higher the score, the greater the impact is on the quality of life
- Change and percent change in Patient-Oriented Eczema Measure (POEM) [ Time Frame: Baseline to Week 14 ]The POEM is a validated 7-item questionnaire used to assess disease symptoms with a scoring system of 1 to 28. The higher score, the higher morbidity.
- Changes in the level of eosinophils in the serum and correlation with other parameters [ Time Frame: Baseline to Week 14 ]The level of biomarkers in serum
- Changes in the level of Thymus Activation Regulated Chemokine (TARC) in the serum and correlation with other parameters [ Time Frame: Baseline to Week 14 ]The level of biomarkers in serum
- Changes in the level of Pulmonary Activation-Regulated Chemokine (PARC) in the serum and correlation with other parameters [ Time Frame: Baseline to Week 14 ]The level of biomarkers in serum
- Changes in the level of eotaxin-3 in the serum and correlation with other parameters [ Time Frame: Baseline to Week 14 ]The level of biomarkers in serum
- Changes in the level of Macrophage-Derived Chemokine (MDC) in the serum and correlation with other parameters [ Time Frame: Baseline to Week 14 ]The level of biomarkers in serum
- Changes in the level of periostin in the serum and correlation with other parameters [ Time Frame: Baseline to Week 14 ]The level of biomarkers in serum
- Changes in the level of total Immunoglobulin E (IgE) in the serum and correlation with other parameters [ Time Frame: Baseline to Week 14 ]The level of biomarkers in serum
- Changes in the level of total Interleukin-13 (IL-13) in the serum and correlation with other parameters [ Time Frame: Baseline to Week 14 ]The level of biomarkers in serum
- Changes in the level of total Interleukin-22 (IL-22) in the serum and correlation with other parameters [ Time Frame: Baseline to Week 14 ]The level of biomarkers in serum
- Changes in the level of total Interleukin-31 (IL-31) in the serum and correlation with other parameters [ Time Frame: Baseline to Week 14 ]The level of biomarkers in serum
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients (males or females) aged 18 years or older
- Patients have documented history of moderate to severe AD, that has been present for at least 1 year
- History of inadequate response to a stable regimen of TCSs or TCIs as treatment for AD
- Patients must agree to apply stable doses of additive-free, basic bland emollient lotions twice daily for at least 7 days before the Baseline Visit
- Willingness and ability to comply with clinic visits and study-related procedures
- Patients should be able to read, understand, and be willing to sign the ICF
Exclusion Criteria:
-
Presence of any of the following laboratory abnormalities
- Hemoglobin < 11 g/dL
- WBC < 3.5 × 103/μL
- Platelet count < 125 × 103/μL
- Neutrophils < 1.75 × 103/μL
- AST/ALT > 1.5 × ULN
- Total bilirubin > ULN
- Creatinine > ULN
- Creatine phosphokinase > ULN
- Positive test for hepatitis B surface antigen, and/or hepatitis C antibody
- Active dermatologic conditions that may confound the diagnosis of AD
- Prior exposure to any investigational systemic treatment or is currently enrolled in another clinical study
- Significant concomitant illness or history of significant illness such as cardiac, renal, neurological, endocrinological, metabolic or lymphatic disease, or any other illness or condition that would adversely affect the patient's participation in this study
- Treatment with TCS, and/or TCI, within 1 week prior to the Baseline Visit
- Known history of human immunodeficiency virus (HIV) infection
- Pregnant or breastfeeding women
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06055374
Contact: Hugh Lee | 1-301-540-2600 | hughlee@kcrnresearch.com |
Responsible Party: | Brexogen Inc. |
ClinicalTrials.gov Identifier: | NCT06055374 |
Other Study ID Numbers: |
BRE-AD01-002 |
First Posted: | September 26, 2023 Key Record Dates |
Last Update Posted: | September 26, 2023 |
Last Verified: | September 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Dermatitis, Atopic Dermatitis Eczema Skin Diseases Skin Diseases, Genetic |
Genetic Diseases, Inborn Skin Diseases, Eczematous Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |